Loading...

Matthew Stachler, MD, PhD

Title(s)Assistant Professor, Pathology
SchoolSchool of Medicine
Phone415-514-1902
EmailMatthew.Stachler@ucsf.edu
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Clinically, I am a Molecular Pathologist focused on using advanced, cutting edge tests to drive personalized medicine in cancer diagnostics and treatment.

    My lab works to understand the process of premalignant progression to invasive cancer, specifically focusing on cancers (esophageal and gastric adenocarcinoma) and pre-malignant conditions (columnar and intestinal metaplasia or Barrett’s esophagus) of the upper gastrointestinal tract as a model system.

    As a disease that is often closely monitored and sampled, Barrett’s esophagus and esophageal adenocarcinoma provides an idea system to study the changes leading up to and driving invasive disease. Additionally, Barrett’s esophagus and esophageal adenocarcinoma are extremely important diseases to understand in their own as esophageal adenocarcinoma has one of the fastest rising incidences of any solid tumor and despite our understanding that it arises from a metaplastic field, we still do an extremely poor job of identifying patients early before advanced disease develops.

    We have taken the approach to first understand the factors important in human tissues through advanced ‘omics’ and digital imaging approaches and then use this understanding to build model systems and functional studies. It is our goal to use the knowledge and understanding gained in these studies to develop novel biomarkers, screening strategies, and treatments to identify and treat people early before advanced disease develops.

    Collapse Research 
    Collapse Research Activities and Funding
    Early TP53 Mutations and Genomic Doubling as a Novel Path for Barrett's Esophagus Progression
    NIH/NIDDK K08DK109209Apr 15, 2016 - Mar 31, 2021
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Featured Publications
    Collapse Websites
    Collapse Collaboration Interests
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Zhang H, Schaefer A, Wang Y, Hodge RG, Blake DR, Diehl JN, Papageorge AG, Stachler MD, Liao J, Zhou J, Wu Z, Akarca FG, de Klerk LK, Derks S, Pierobon M, Hoadley KA, Wang TC, Church G, Wong KK, Petricoin EF, Cox AD, Lowy DR, Der CJ, Bass AJ. Gain-of-Function RHOA Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer. Cancer Discov. 2019 Nov 26. PMID: 31771969.
      View in: PubMed
    2. Stachler MD. Colorectal Adenocarcinoma, Not Just One Disease. Cell Mol Gastroenterol Hepatol. 2019; 8(2):293-294. PMID: 31129094.
      View in: PubMed
    3. Soong TR, Nayor J, Stachler MD, Perencevich M, Jajoo K, Saltzman JR, Lindeman NI, Srivastava A. Clinicopathologic and genetic characteristics of interval colorectal carcinomas favor origin from missed or incompletely excised precursors. Mod Pathol. 2019 May; 32(5):666-674. PMID: 30455417.
      View in: PubMed
    4. Qureshi AP, Stachler MD, Haque O, Odze RD. Biomarkers for Barrett's esophagus - a contemporary review. Expert Rev Mol Diagn. 2018 11; 18(11):939-946. PMID: 30345836.
      View in: PubMed
    5. Yu M, Maden SK, Stachler M, Kaz AM, Ayers J, Guo Y, Carter KT, Willbanks A, Heinzerling TJ, O'Leary RM, Xu X, Bass A, Chandar AK, Chak A, Elliott R, Willis JE, Markowitz SD, Grady WM. Subtypes of Barrett's oesophagus and oesophageal adenocarcinoma based on genome-wide methylation analysis. Gut. 2018 Jun 08. PMID: 29884612.
      View in: PubMed
    6. Stachler MD, Camarda ND, Deitrick C, Kim A, Agoston AT, Odze RD, Hornick JL, Nag A, Thorner AR, Ducar M, Noffsinger A, Lash RH, Redston M, Carter SL, Davison JM, Bass AJ. Detection of Mutations in Barrett's Esophagus Before Progression to High-Grade Dysplasia or Adenocarcinoma. Gastroenterology. 2018 07; 155(1):156-167. PMID: 29608884.
      View in: PubMed
    7. Johncilla M, Stachler M, Misdraji J, Lisovsky M, Yozu M, Lindeman N, Lauwers GY, Odze RD, Srivastava A. Mutational landscape of goblet cell carcinoids and adenocarcinoma ex goblet cell carcinoids of the appendix is distinct from typical carcinoids and colorectal adenocarcinomas. Mod Pathol. 2018 06; 31(6):989-996. PMID: 29422640.
      View in: PubMed
    8. Pectasides E, Stachler MD, Derks S, Liu Y, Maron S, Islam M, Alpert L, Kwak H, Kindler H, Polite B, Sharma MR, Allen K, O'Day E, Lomnicki S, Maranto M, Kanteti R, Fitzpatrick C, Weber C, Setia N, Xiao SY, Hart J, Nagy RJ, Kim KM, Choi MG, Min BH, Nason KS, O'Keefe L, Watanabe M, Baba H, Lanman R, Agoston AT, Oh DJ, Dunford A, Thorner AR, Ducar MD, Wollison BM, Coleman HA, Ji Y, Posner MC, Roggin K, Turaga K, Chang P, Hogarth K, Siddiqui U, Gelrud A, Ha G, Freeman SS, Rhoades J, Reed S, Gydush G, Rotem D, Davison J, Imamura Y, Adalsteinsson V, Lee J, Bass AJ, Catenacci DV. Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discov. 2018 01; 8(1):37-48. PMID: 28978556.
      View in: PubMed
    9. Zhou J, Wu Z, Wong G, Pectasides E, Nagaraja A, Stachler M, Zhang H, Chen T, Zhang H, Liu JB, Xu X, Sicinska E, Sanchez-Vega F, Rustgi AK, Diehl JA, Wong KK, Bass AJ. CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma. Nat Commun. 2017 01 06; 8:13897. PMID: 28059068.
      View in: PubMed
    10. Stachler MD, Rinehart EM, Garcia E, Lindeman NI. PIK3CA Mutations are Common in Many Tumor Types and are Often Associated With Other Driver Mutations. Appl Immunohistochem Mol Morphol. 2016 May-Jun; 24(5):313-9. PMID: 26067136.
      View in: PubMed
    11. Stachler MD, Taylor-Weiner A, Peng S, McKenna A, Agoston AT, Odze RD, Davison JM, Nason KS, Loda M, Leshchiner I, Stewart C, Stojanov P, Seepo S, Lawrence MS, Ferrer-Torres D, Lin J, Chang AC, Gabriel SB, Lander ES, Beer DG, Getz G, Carter SL, Bass AJ. Paired exome analysis of Barrett's esophagus and adenocarcinoma. Nat Genet. 2015 Sep; 47(9):1047-55. PMID: 26192918.
      View in: PubMed
    12. Derks S, Nason KS, Liao X, Stachler MD, Liu KX, Liu JB, Sicinska E, Goldberg MS, Freeman GJ, Rodig SJ, Davison JM, Bass AJ. Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma. Cancer Immunol Res. 2015 Oct; 3(10):1123-1129. PMID: 26081225.
      View in: PubMed
    13. Stachler M, Jia Y, Sharaf N, Wade J, Longtine J, Garcia E, Sholl LM. Filter Paper-based Nucleic Acid Storage in High-throughput Solid Tumor Genotyping. Appl Immunohistochem Mol Morphol. 2015 May-Jun; 23(5):389-96. PMID: 25221956.
      View in: PubMed
    14. Kaz AM, Grady WM, Stachler MD, Bass AJ. Genetic and Epigenetic Alterations in Barrett's Esophagus and Esophageal Adenocarcinoma. Gastroenterol Clin North Am. 2015 Jun; 44(2):473-89. PMID: 26021206.
      View in: PubMed
    15. Stachler MD, Rinehart E, Lindeman N, Odze R, Srivastava A. Novel molecular insights from routine genotyping of colorectal carcinomas. Hum Pathol. 2015 Apr; 46(4):507-13. PMID: 25683705.
      View in: PubMed
    16. Hong YS, Kim J, Pectasides E, Fox C, Hong SW, Ma Q, Wong GS, Peng S, Stachler MD, Thorner AR, Van Hummelen P, Bass AJ. Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models. PLoS One. 2014; 9(10):e109440. PMID: 25350844.
      View in: PubMed
    17. Baden LR, Liu J, Li H, Johnson JA, Walsh SR, Kleinjan JA, Engelson BA, Peter L, Abbink P, Milner DA, Golden KL, Viani KL, Stachler MD, Chen BJ, Pau MG, Weijtens M, Carey BR, Miller CA, Swann EM, Wolff M, Loblein H, Seaman MS, Dolin R, Barouch DH. Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans. J Infect Dis. 2015 Feb 15; 211(4):518-28. PMID: 25165165.
      View in: PubMed
    18. Kanarek N, Grivennikov SI, Leshets M, Lasry A, Alkalay I, Horwitz E, Shaul YD, Stachler M, Voronov E, Apte RN, Pagano M, Pikarsky E, Karin M, Ghosh S, Ben-Neriah Y. Critical role for IL-1ß in DNA damage-induced mucositis. Proc Natl Acad Sci U S A. 2014 Feb 11; 111(6):E702-11. PMID: 24469832.
      View in: PubMed
    19. Baker K, Rath T, Flak MB, Arthur JC, Chen Z, Glickman JN, Zlobec I, Karamitopoulou E, Stachler MD, Odze RD, Lencer WI, Jobin C, Blumberg RS. Neonatal Fc receptor expression in dendritic cells mediates protective immunity against colorectal cancer. Immunity. 2013 Dec 12; 39(6):1095-107. PMID: 24290911.
      View in: PubMed
    20. Giardino AA, Ramaiya NH, Shinagare AB, Jagannathan JP, Stachler MD, Raut CP. Case report: Calcifying fibrous tumor presenting as an asymptomatic pelvic mass. Indian J Radiol Imaging. 2011 Oct; 21(4):306-8. PMID: 22223947.
      View in: PubMed
    21. Stachler MD, Chen I, Ting AY, Bartlett JS. Site-specific modification of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol Ther. 2008 Aug; 16(8):1467-73. PMID: 18560418.
      View in: PubMed
    22. Stachler MD, Bartlett JS. Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 2006 Jun; 13(11):926-31. PMID: 16482202.
      View in: PubMed
    23. Arnold GS, Sasser AK, Stachler MD, Bartlett JS. Metabolic biotinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol Ther. 2006 Jul; 14(1):97-106. PMID: 16624620.
      View in: PubMed
    Matthew's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Similar People
    People who share similar concepts with this person.
    _
    Same Department